Clonazepam in a Focal‐Motor Monkey Model: Efficacy, Tolerance, Toxicity, Withdrawal, and Management

@article{Lockard1979ClonazepamIA,
  title={Clonazepam in a Focal‐Motor Monkey Model: Efficacy, Tolerance, Toxicity, Withdrawal, and Management},
  author={J. Lockard and R. Levy and W. C. Congdon and L. L. DuCharme and L. Salonen},
  journal={Epilepsia},
  year={1979},
  volume={20}
}
Summary: Since the clinical data have been equivocal in regard to the effects of clonazepam (CZP) in focal‐motor seizures, an alumina gel monkey model was used to evaluate quantitatively its efficacy with respect to this seizure category. The insolubility of CZP and its short biological half‐life in monkey necessitated its evaluation in the model via constant‐rate intravenous administration in a solution of polyethylene glycol 400 (PEG). Two groups of monkeys were given CZP in PEG (N= 6) or a… Expand
13 Citations
Failure of carbamazepine to prevent clonazepam withdrawal status epilepticus
Chapter 61 – Withdrawal Seizures
Primate Models of Neurological Disease
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Pharmacokinetic profile of clonazepam in rhesus monkeys.
Clonazepam. A review of a new anticonvulsant drug.
CLONAZEPAM IN THE TREATMENT OF EPILEPSY
ASSAY AND PHARMACOKINETICS OF CLONAZEPAM IN HUMANS
THE USE OF CLONAZEPAM AS AN ANTICONVULSANT—CLINICAL EVALUATION
  • P. Bladin
  • Medicine
  • The Medical journal of Australia
  • 1973
Dipropylacetic acid and ethosuximide in monkey model : Quantitative methods of evaluation
  • Quantitative Analytic Studies in Epilepsy
  • 1976
...
1
2
...